Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients age 18 years or older to less than 65 years, inclusive (at time of informed consent)~* Subjects with a current diagnosis of schizophrenia, as defined by DSM-IV-TR criteria and a history of the illness for at least three years prior to screening (as per subject, family, healthcare provider, or by previous medical records).~* Subjects with a stable living environment, as demonstrated by the ability to provide contact information for themselves and/or family/friend(s)/caregiver(s).~* Subjects who showed previous response to antipsychotic treatment in the past year.~* Subjects who are currently treated with oral or depot antipsychotics other than clozapine or who have had a recent lapse in antipsychotic treatment requiring chronic treatment with antipsychotic medication for stabilization.~* Subjects who are experiencing a current acute exacerbation of psychotic symptoms requiring stabilization~* Subjects with a history of relapse and/or exacerbation of symptoms when they are not receiving antipsychotic treatment.~Exclusion Criteria:~* Female patients who are breastfeeding or who have a positive pregnancy test (urine) result prior to receiving investigational medicinal product~* Patients presenting a first episode of schizophrenia based on the clinical judgment of the investigator~* Patients who are diagnosed with a disease other than schizophrenia (schizoaffective disorder, major depressive disorder, bipolar disorder, posttraumatic stress disorder, anxiety disorder, delirium, dementia, amnesia, or other cognitive disorder) based on current DSM-IV-TR Axis Ι criteria, or who are diagnosed with a personality disorder (borderline, paranoid, histrionic, schizotypal, schizoid, or antisocial)~* Subjects experiencing acute depressive symptoms within the past 30 days~* Subjects with schizophrenia who are considered resistant/refractory to antipsychotic treatment by history~* Subjects with a significant risk of violent behavior; who represent a risk of committing suicide~* Subjects with clinically significant tardive dyskinesia~* Subjects currently treated with insulin for diabetes.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo comparator for 52 weeks
- Brexpiprazole (OPC-34712) (Type: EXPERIMENTAL): Brexpiprazole (OPC-34712) for 52 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).